Core Insights - Cognition Therapeutics, Inc. reported a 95% reduction in cognitive decline in patients treated with CT1812 who had lower plasma p-tau217 levels, indicating the drug's potential to modify the disease progression of Alzheimer's [1][2][3] Group 1: Study Findings - The Phase 2 'SHINE' study involved 153 adults with mild-to-moderate Alzheimer's disease, focusing on safety, tolerability, and cognitive function [4] - Participants with lower plasma p-tau217 levels experienced a 2.7-point improvement on the ADAS-Cog11 scale compared to placebo over six months [2][4] - Key biomarkers reflecting Alzheimer's disease pathology showed normalization in CT1812-treated participants, including reductions in GFAP, NfL, Aβ42, and Aβ40 [3][4] Group 2: Future Plans - The company plans to present comprehensive biomarker results at scientific conferences in 2025 and intends to meet with the FDA to discuss the findings and Phase 3 program design [3][4] - Ongoing recruitment for the START study and completed enrollment in the SHIMMER study indicate the company's commitment to advancing CT1812's clinical development [9][10] Group 3: About CT1812 - CT1812 is an experimental small molecule that targets the sigma-2 receptor complex, aiming to displace toxic Aβ oligomers and regulate cellular processes affected by Alzheimer's disease [8] - The median baseline level of plasma p-tau217 in the SHINE study was found to be 1.0 pg/mL, with participants categorized based on levels above or below this median [6][7]
Cognition Therapeutics' Analysis Correlates Biomarker Changes with Cognitive Benefit in Alzheimer's Population